Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Chao H Huang"'
Autor:
Chao H Huang, Stephen K Williamson, Prakash eNeupane, Sarah A Taylor, Ace eAllen, Nora J Smart, Adelina M Uypeckcuat, Sarah eSpencer, Jo eWick, Holly eSmith, Peter J Van Veldhuizen, Karen eKelly
Publikováno v:
Frontiers in Oncology, Vol 5 (2016)
Background: Insulin-like growth factor 1 receptor (IGF-1R) regulates cell growth, proliferation and apoptosis. Adenocarcinoma and never-smokers have a higher expression of IGF-1R, which is associated with worse overall survival. Dalotuzumab-MK0646 (D
Externí odkaz:
https://doaj.org/article/d6ef07d5512e44d4ba18480f63ccc3f9
Autor:
Chao H Huang, Jo eWick, Gurusingham (Sitta) eSittampalam, Victor Sanjit eNirmalanandhan, Apar eGanti, Stephen K Williamson, Prakash C Neupane, Andrew eGodwin, Sarah eSchmitt, Nora J Smart, Sarah eSpencer, Peter J Van Veldhuizen
Publikováno v:
Frontiers in Oncology, Vol 4 (2014)
Abstract Background: SCLC, a variant of lung cancer marked by early metastases, accounts for 13% of all lung cancers diagnosed in US. Despite high response rates to treatment, it is an aggressive disease with a median survival of 9-11 months for pati
Externí odkaz:
https://doaj.org/article/c099dbe53c4d4a3896caacf2d951b043
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
The therapeutic landscape for patients with non-small cell lung cancer (NSCLC) has dramatically evolved with the development and adoption of immune checkpoint inhibitors (ICI) as front-line therapy. These novel antibodies target the interactions in i
Externí odkaz:
https://doaj.org/article/f32fadc168354053b6c78bbc6d031b5e
Autor:
Tahani Atieh, Chao H. Huang
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
LCNEC of the lung comprises a small proportion of pulmonary malignancies. Traditionally, they have been classified based on histologic and immunohistochemistry characteristics with features of small cell and non-small cell lung cancer. The treatment
Externí odkaz:
https://doaj.org/article/aef1996b001f40dc882eae92539a4ae9
Autor:
J. Nicholas Bodor, Jyoti D. Patel, Heather A. Wakelee, Benjamin P. Levy, Hossein Borghaei, Bruna Pellini, Michael R. Costello, Jonathan E. Dowell, Gene Finley, Chao H Huang, Joel W. Neal, Jorge J Nieva, Sonam Puri, Mark A. Socinski, Christian Thomas, Eric A. Ross, Samuel Litwin, Margie L. Clapper, Joseph Treat
Publikováno v:
Clinical Lung Cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da2fbf4307a7ba7d2b55051d07a1baaa
https://doi.org/10.1016/j.cllc.2023.05.003
https://doi.org/10.1016/j.cllc.2023.05.003
Autor:
Takefumi Komiya, Chao H. Huang
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Recent application of immunotherapy in clinical oncology revolutionized our management of advanced human cancers. Check point inhibitors targeting CTLA4 and PD-1/PD-L1 axis are immunotherapeutic agents currently available to treat a variety of cancer
Externí odkaz:
https://doaj.org/article/07997fea336746e0b1ce7a0bb62856e9
Autor:
Chao H. Huang, John B. A. G. Haanen, Mehmet Altan, Faitg Thomas H, Brian H. Ladle, Adrian G. Sacher, Adam J. Schoenfeld, Taofeek K. Owonikoko, Dejka M. Araujo, Aisha N. Hasan, Sandra P. D'Angelo, Aiman Shalabi, Steven Attia, Jeffrey Yachnin, Brian A. Van Tine, David A. Liebner, Emily Butler, Jonathan Noujaim, Kai He
Publikováno v:
Journal of Clinical Oncology. 39:TPS2661-TPS2661
TPS2661 Background: Letetresgene autoleucel (lete-cel; GSK3377794) is an autologous T-cell therapy using a genetically modified T-cell receptor (TCR) to improve recognition of cancer cells expressing NY-ESO-1/LAGE-1a. Next generation NY-ESO-1 TCR T-c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8b9fdb3bd95581f082b633cf36a3fa3
https://doi.org/10.1200/jco.2021.39.15_suppl.tps2661
https://doi.org/10.1200/jco.2021.39.15_suppl.tps2661
Autor:
Andrew K. Godwin, Inamul Haque, Sushanta K. Banerjee, Arvind Subramanian, Peter J. Van Veldhuizen, Chao H. Huang, Snigdha Banerjee
Publikováno v:
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 19, Iss 1, p 107 (2017)
International Journal of Molecular Sciences, Vol 19, Iss 1, p 107 (2017)
Renal Cell Carcinoma (RCC) is the most prominent kidney cancer derived from renal tubules and accounts for roughly 85% of all malignant kidney cancer. Every year, over 60,000 new cases are registered, and about 14,000 people die from RCC. The inciden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4f52cfeac9f4926038675f3482a4e98
http://europepmc.org/articles/PMC5796057
http://europepmc.org/articles/PMC5796057
Publikováno v:
Thoracic Cancer. 5:565-569
Severe (grade 3 or higher) esophagitis is one of the major toxicities for chemoradiation in the treatment of stage III non-small cell lung cancer (NSCLC). The difference among ethnic groups has never been investigated in detail. Prospective trials wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7a5230b3c68ddb7fd091627e2340c3c
https://doi.org/10.1111/1759-7714.12141
https://doi.org/10.1111/1759-7714.12141
Publikováno v:
Journal of Thoracic Oncology. 14:S1140
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b732a9d0e380925b3bd18dfe166cd882
https://doi.org/10.1016/j.jtho.2019.09.054
https://doi.org/10.1016/j.jtho.2019.09.054